Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00123669
Status:
COMPLETED
Last Update Posted:
2020-07-22
First Post:
2005-07-21
Brief Title:
Primary Progesterone Therapy for Operable Breast Cancer
Sponsor:
Tata Memorial Hospital
Organization:
Tata Memorial Hospital
Study Overview
Official Title:
The Primary Progesterone Therapy for Operable Breast Cancer A Randomized Controlled Trial
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test the effect of primary progesterone on overall and disease free survival in women with operable breast cancer The study addresses two issues related to breast cancer surgery
Circulating progesterone at the time of surgery might counteract the detrimental effect of estrogen on survival of women with operable breast cancer
Events at the time of surgery may have an impact on the natural history of breast cancer
Circulating progesterone at the time of surgery might counteract the detrimental effect of estrogen on survival of women with operable breast cancer
Events at the time of surgery may have an impact on the natural history of breast cancer
Detailed Description:
This protocol addresses the issue of pre-operative hormone manipulation in women with operable breast cancer The study has been designed after careful review of literature to assess the effect of unopposed oestrogen at the time of surgery and collect evidence that events at the time of surgery may have impact on the long-term survival of breast cancer patients The meta-analysis of 37 studies on timing of surgery during the menstrual cycle showed a 15 3 improvement in survival for women who had undergone surgery during the luteal phase of their menstrual cycle Three of the 37 studies where progesterone levels were estimated at the time of surgery showed 52 26 improvement in survival when circulating progesterone were 15 ngml The study aims to produce luteal milieu by injecting Hydroxy- progesterone 500 mg IM at the time of surgery The timing of administration of progesterone in the neo-adjuvant setting is decided after collating data from large data-bases and randomised trials of screening suggesting that events at the time of surgery may alter the behavior of micro-metastases
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None